The FDA has lifted a partial clinical hold on the Phase I/II TakeAim Leukemia trial of emavusertib as monotherapy and in combination with azacytidine and venetoclax for the treatment of patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome.
[Targeted Oncology]
